SHD

Across TCGA pan-cancer cohorts, SHD Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SHD data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher SHD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SHD expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

KIRC, SKCM, and PRAD are the cancer types where SHD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.167	0.655	.038	12	view →
SKCM	DFS	Median	III,IV	1.000	0.595	.012	11	view →
PRAD	DFS	Median	All	0.149	0.777	<.001	6	view →
LGG	DFS	Median	All	0.555	0.832	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SHD–KIRC (OS)

Open the KIRC breakdown →